MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • VolitionRX Ltd. (VNRX) Focused On Making Cancer Detection Simple And Routine 0 comments
    Jan 27, 2014 5:20 PM | about stocks: VNRX

    The early detection of cancer is considered crucial in developing a truly effective approach to dealing with the disease. There are, of course, many types of cancers, but early detection, before symptoms develop, could have a dramatic effect on the ability of doctors to successfully treat the disease before its spread makes it untreatable. In conjunction with the need for early detection is the search for a relatively simple and non-invasive method of detection. Less invasive tests would make it easier for patients, encouraging them to go in for tests, and it would also lower costs. With such technologies, it's possible that cancer screening could someday become routine across the general population, making successful outcomes far more likely.

    VolitionRx is developing unique blood-based cancer diagnostic tests. The company's proprietary Nucleosomics technology, and associated NuQ assays, can effectively spot and measure nucleosome structures in the blood, a red flag for the presence of cancerous cells. Positive results in early tests have led the company to recently announce the commencement of effectiveness trials on a larger scale. In collaboration with Hvidovre Hospital in Denmark, samples collected earlier from 4,800 patients are being put through a blind retrospective study to further confirm the accuracy of the company's NuQ assays for the initial screening of colorectal cancer. The samples assessed in the study are from patients who have undergone a colonoscopy and have confirmed presence or absence of colorectal cancer, other malignancies, polyps, or benign bowel diseases. Early tests displayed 85% detection rates for colorectal cancer and more than 50% of precancerous polyps.

    In addition, the company is also developing HyperGenomics, designed to detect specific signatures from cancer biopsies by reading hypersensitive sites along the DNA string. The idea is to better identify subtypes of the disease, allowing more highly focused therapies.

    For additional information, visit volitionrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: VNRX
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.